Advanced Solid Tumours
Conditions
Keywords
PG545, Phase I, Progen, antimetastatic, antiangiogenic, advanced cancer patients, solid tumors, solid tumours, tumor microenvironment
Brief summary
This Phase Ia study aims to establish the maximum tolerated dose of once-weekly IV infused PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition, the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.
Interventions
DRUGPG545
PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
Sponsors
Zucero Pty Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>=18 years. * Histological or cytological documentation of non hematologic, malignant solid tumour. * Have failed at least one previous therapeutic regimen. * LIfe expectancy \>= 12 weeks. * ECOG performance status 0 or 1. * Written, signed and dated informed consent. * Able and willing to meet all protocol-required treatments, investigations and visits. * Have adequate organ function.
Exclusion criteria
* Clinically significant non-malignant disease. * Active CNS metastases. * Subjects with uncontrolled diabetes. * History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents * Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose), heparin within two weeks prior to randomisation, or other anti-platelet drugs. * History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media. * Known seropositivity to the human immunodeficiency vies (HIV) * Women who are pregnant or breast feeding * Women of child-bearing potential and male subjects who are partners of women of child bearing potential who are unable or unwilling to use effective means of contraception. * Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of maximum tolerated dose (MTD) of PG545 | Evaluated at the end of initial 28-day cycle | The MTD will be determined by assessing dose limiting toxicities at the end of the first month's treatment. Dose escalation and de-escalation will continue until an MTD is identified. Each cohort of patients will receive weekly doses at a single dose level for the duration of the study. |
Secondary
| Measure | Time frame |
|---|---|
| Number of adverse events by cohort | Subjects will be followed for the duration of their treatment (an expected average of 12 weeks), and for four weeks post-treatment |
| Severity of adverse events by cohort | Subjects will be followed for the duration of their treatment (an expected average of 12 weeks), and for four weeks post-treatment |
| Assessment of the anti-tumour activity of PG545 using RECIST criteria | Subjects will be followed for the duration of their treatment (an expected average of 12 weeks), and then up to four weeks post-treatment |
Countries
Australia
Outcome results
None listed